Madrigal
NASDAQ: MDGLConshohocken, US · Founded 2011 · 3 known investors
Find your way into Madrigal
Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH). The company focuses on improving care for patients with this liver disease through innovative drug development and collaboration.
Founders & leadership
Madrigal was founded in 2011 by Rebecca Taub.
RT
MR
Marc R. SchneebauminSVP and CFO2016–2021Marc R. Schneebaum is Executive Officer at Madrigal Pharmaceuticals, a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis. He brings experience in life sciences across medtech and biotech, as well as investment banking and financial services.
PA
BS
Bill SiboldinChief Executive OfficerBill Sibold is President and CEO of Madrigal Pharmaceuticals, a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis.
MD
Mardi DierinChief Financial Officer
CH
Carole HuntsmaninChief Commercial Officer (CCO)Carole Huntsman held executive leadership positions at Sanofi and EMD Serono in pharmaceutical commercial strategy and product launches across multiple therapeutic areas, serving as US country lead at Sanofi and holding an MBA from Boston College. She joined Madrigal as Executive Vice President and Chief Commercial Officer.
SK
Shannon KelleyinChief Legal Officer & Corporate Secretary
DS
David SoergelinChief Medical OfficerHe is a pediatric cardiologist with prior experience in early and late phase clinical development, experimental medicine, and regulatory affairs across multiple therapy areas at large pharmaceutical and biotech companies.
Board
FC
LC
KR
Keith R. GollustBoard director
DM
David MilliganBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$38.4M disclosed across 2 rounds · 2016–2017
▶$35MraisedJul 2017 · 5 investors · PharmaceuticalsRule 506(b)
▶$35MraisedJul 2017 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fred B. CravesDirector
- Marc R. SchneebaumExecutive Officer
- Keith R. GollustDirector
- Kenneth M. BateDirector
- Richard S. LevyDirector
- Paul A. FriedmanExecutive Officer, Director
- Rebecca TaubDirector
- David MilliganDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedApr 2016 · 4 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedApr 2016 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fred CravesDirector
- Rebecca TaubExecutive Officer, Director
- Lionel CarnotDirector
- Offering amount
- $9M
- Amount sold
- $3.4M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?finance.yahoo.com · Sep 2026
Madrigal Sets Investor Presentation as MASH Strategy Advances - MyChesComychesco.com · Aug 2026Frequently asked questions
- What does Madrigal do?
- Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH). The company focuses on improving care for patients with this liver disease through innovative drug development and collaboration.
- Who founded Madrigal?
- Madrigal was founded by Rebecca Taub in 2011.
- Who are Madrigal's investors?
- Madrigal's investors include Avoro Capital Advisors, Bay City Capital, Foresite Capital.
- How much funding has Madrigal raised?
- Madrigal has disclosed $38.4M raised across 2 rounds.
- Where is Madrigal headquartered?
- Madrigal is headquartered in Conshohocken, US.